Smoldering Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Smoldering Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
This clinical trial update describes a study using integrative multi-omics analysis to predict the clinical evolution of monoclonal gammopat…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
An observational prospective study at MD Anderson Cancer Center investigating monoclonal gammopathies that progress to myeloma; the trial is…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma [Phase 2]
Phase 2 trial evaluating iberdomide alone or in combination with dexamethasone for intermediate- or high-risk smoldering multiple myeloma is…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) [NA]
A clinical trial protocol comparing a plant-based diet with supplements and a placebo in people with Monoclonal Gammopathy of Undetermined S…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
A clinical trial in Italy (ProDigALIty) aims to promote diagnosis and management of AL amyloidosis and related plasma cell disorders and is …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
This clinical trial update notes a study recruiting to assess quality of life in patients with asymptomatic monoclonal gammopathies, includi…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) [Phase 2]
A Phase 2 clinical trial update on isatuximab with or without lenalidomide for patients at high risk of progression from smoldering multiple…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma [Phase 2]
A Phase 2 proof-of-concept trial is evaluating the safety and activity of linvoseltamab in adults with smoldering multiple myeloma at high r…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
The document provides a clinical trial update from the University of Miami describing two distinct precursor states of multiple myeloma—prog…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma [Phase 2]
Phase 2 proof-of-concept trial assessing Linvoseltamab in adults with high-risk Monoclonal Gammopathy of Undetermined Significance or non-hi…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma [Phase 3]
A Phase 3 clinical trial evaluating lenalidomide and dexamethasone with or without daratumumab in patients with high-risk smoldering multipl…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma [NA]
A prospective multicenter trial is evaluating the effects of plant-based diets on the gut microbiome and derived metabolites in patients wit…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma [Phase 2]
This Phase 2 trial update describes subcutaneous daratumumab, once-weekly carfilzomib, and dexamethasone (DKd) in patients with high-risk sm…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
A clinical trial registry update from Dana-Farber Cancer Institute notes a study involving questionnaires and tissue banking for multiple my…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers [NA]
A clinical trial is evaluating a 12-month multimodal lifestyle management program and its effect on disease-relevant biomarkers in individua…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM [Phase 1]
Phase 1 study evaluating PVX-410 cancer vaccine with citarinostat, with or without lenalidomide, in patients with smoldering multiple myelom…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: CAR- PRISM (PRecision Intervention Smoldering Myeloma) [Phase 2]
Phase 2 trial update for CAR-PRISM, a cellular therapy for multiple myeloma and smoldering multiple myeloma, sponsored by Dana-Farber Cancer…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients [Phase 2]
Phase 2 clinical trial evaluating leflunomide for high-risk smoldering multiple myeloma in African-American and European-American patients; …
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease [NA]
This entry describes the FAST-M trial evaluating prolonged overnight fasting with a Mediterranean diet for patients with multiple myeloma or…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) [Phase 2]
This is a Phase 2 clinical trial update (REVIVE) evaluating teclistamab in combination with daratumumab for high-risk smoldering/wholedown m…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
The document updates on a University of Utah–sponsored clinical trial evaluating high-risk smoldering multiple myeloma with long-term observ…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
A Dana-Farber Cancer Institute-led clinical study recruiting to investigate molecular progression and clinical outcomes in MGUS, smoldering …
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS/SMM: A Pilot Study [NA]
A pilot clinical trial evaluating the effects of a Korean-style Mediterranean diet (KORMED) and physical activity measurement in patients wi…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
The CHAAMP internal pilot study is currently recruiting. It targets multiple myeloma and related plasma cell disorders, including MGUS and s…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma [Phase 1]
Phase 1 open-label trial of belantamab mafodotin in high-risk smoldering multiple myeloma is ongoing, with an extension cohort at a single c…